A5070079416- Asthma and respiratory diseases
- Respiratory and Cough-Related Research
- Eosinophilic Esophagitis
- Inhalation and Respiratory Drug Delivery
- Allergic Rhinitis and Sensitization
- IL-33, ST2, and ILC Pathways
- COVID-19 Clinical Research Studies
- Pneumonia and Respiratory Infections
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Pediatric health and respiratory diseases
- Long-Term Effects of COVID-19
- Respiratory viral infections research
- Sinusitis and nasal conditions
- Pharmaceutical studies and practices
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Pneumocystis jirovecii pneumonia detection and treatment
- Urticaria and Related Conditions
- Eosinophilic Disorders and Syndromes
- Cystic Fibrosis Research Advances
- Tracheal and airway disorders
- Respiratory Support and Mechanisms
- Otitis Media and Relapsing Polychondritis
- Nosocomial Infections in ICU
- Neonatal Respiratory Health Research
- SARS-CoV-2 and COVID-19 Research
AULSS 2 Marca Trevigiana
2023-2024
Ito Hospital
2023-2024
Ca' Foncello Hospital
2023
Ospedale Santa Maria
2015-2022
Azienda Sanitaria Unità Locale di Reggio Emilia
2017-2022
Istituti di Ricovero e Cura a Carattere Scientifico
2014-2021
Santa Maria Nuova Hospital
2009-2021
University of Milan
2018-2021
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2018-2021
Azienda Ospedaliera S.Maria
2012-2021
BackgroundAsthma is one of the most common non-communicable respiratory diseases, affecting about 6% general population. Severe asthma, even if afflicts a minority asthmatics, drives majority costs disease. The aim this study to create pharmacoeconomic model predict corticosteroid-related adverse events in severe asthmatics and applying it first published epidemiologic data from Asthma Network Italy (SANI) registry.MethodsThe analysis was conducted perspective Italian National Healthcare...
During this long COVID-19 pandemic outbreak, continuous positive airway pressure (CPAP) and noninvasive ventilation (NIV) are being widely used to treat patients with moderate severe acute respiratory failure (ARF). As for now, data on the efficacy of NIV in distress syndrome (ARDS) lacking, reason it is extremely important accurately determine outcomes strategy. This study aimed evaluate clinical ARDS.Seventy-nine consecutive sudden worsening were evaluated. All (71% male) had a confirmed...
Background: Benralizumab has been shown to restore good control of severe eosinophilic asthma (SEA). Robust data on benralizumab effectiveness over periods longer than 2 years are scarce. Methods: This retrospective multicentric study was conducted 108 Italian SEA patients treated with for up 36 months. Partial and complete clinical remission (CR) were assessed. Data analyzed descriptive statistics or using linear, logistic, negative binomial mixed-effect regression models. Results: At...
CPAP is the standard treatment for obstructive sleep apnea (OSA), but as many 50% of patients discontinue its use, within three years. The PROTEUS project aims to enhance adherence through telemonitoring. OSA undergoing since July 2018, had an in-person reassessment after months, followed by quarterly telemonitoring providers, who intervened in cases poor (less than 4 h·night-1 or less 70% days), excessive mask leakage, elevated residual apnea-hypopnea index (rAHICPAP). A total 486 (~87%)...
Omalizumab is frequently used as add-on treatment to inhaled corticosteroids (ICS) and long-acting β2-agonists in patients with suboptimal control of severe asthma. Patients asthma will typically require chronic treatment, although due the limited amount data available there are still some concerns about safety efficacy long-term therapy omalizumab. Herein, an extension a previous 4-year study, we report disease-related outcomes 8 persistent allergic who have been followed for total 9 years...
The severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is extremely variable, ranging from asymptomatic patients to those who develop distress (ARDS). As for now, there are still no really effective therapies disease 2019 (COVID-19). Some evidences suggest that tocilizumab (TCZ) may avoid the progression COVID-19. aim this retrospective case-control study was analyze efficacy and safety TCZ in with COVID-19 ARDS undergoing noninvasive mechanical ventilation (NIV).
Abstract: The increasing knowledge on inflammatory pathways has driven the development of targeted biological therapies for severe refractory asthma. Among recently developed biologics, fully human monoclonal antibody dupilumab is an interesting therapeutic option, given its ability to inhibit effects both IL-4 and IL-13. We describe case a male, Caucasian, 56-year-old patient with allergic eosinophilic Given poor asthma control, he started treatment add-on dupilumab, after tenth injection,...
Clinically meaningful improvement in the Sino-Nasal Outcome Test-22 (SNOT-22) was observed patients with severe, eosinophilic asthma, and nasal polyposis (NP) treated benralizumab ANDHI trial. A post hoc assessment of effects on SNOT-22 response asthma efficacy measures these conducted for further characterization safety severe NP.Adults who had experienced ≥2 prior-year exacerbations despite high-dosage inhaled corticosteroid plus additional controller[s] were randomized to 24 weeks or...
The efficacy of benralizumab has been broadly demonstrated in severe eosinophilic asthma (SEA), but only few real-life studies evaluated its long-term effects. Here we present novel data from the ANANKE study which a large cohort SEA patients was treated for up to 96 weeks.ANANKE (NCT04272463) is an observational retrospective Italian investigating key characteristics (collected during 12 months prior initiation) and clinical outcomes treatment (annual exacerbation rate [AER], lung function,...
Introduction Dupilumab, a monoclonal antibody targeting the IL-4 receptor alpha subunit, effectively blocks both and IL-13 mediated pathways. Its introduction has represented significant advancement in treatment of severe asthma other Type 2 (T2) conditions, including nasal polyps, atopic dermatitis, eosinophilic esophagitis. To date, Dupilumab demonstrated optimal efficacy safety profile.
Bronchial thermoplasty (BT) is a non-pharmacological intervention for severe asthma whose mechanism of action not completely explained by reduction airway smooth muscle (ASM). In this study we analyzed the effect BT on nerve fibers and inflammatory components in bronchial mucosa at 1 year.Endobronchial biopsies were obtained from 12 subjects (mean age 47 ± 11.3 years, 50% male) with asthma. Biopsies performed baseline (T0) after (T1), 2 (T2) (T12) months post-BT, studied immunocytochemistry...
Abstract Background Data from phase 3 trials have demonstrated the efficacy and safety of benralizumab in patients with severe eosinophilic asthma (SEA). We conducted a real-world study examining baseline characteristics large SEA population treated clinical practice assessed therapy effectiveness. Methods ANANKE is an Italian multi-center, retrospective cohort including consecutive who had started ≥ months before enrolment (between December 2019 July 2020), setting. collection covered (1)...